Urinary Tract, Sexual Organs, and Pregnancy Conditions  >>  OvaRex (oregovomab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OvaRex (oregovomab) / CanariaBio
NCT00034372: Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma

Terminated
2
102
US, Canada
oregovomab
Unither Pharmaceuticals
Ovarian Neoplasms
 
12/07
NCT00086632: Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

Terminated
2
40
US
oregovomab
Unither Pharmaceuticals
Ovarian Cancer
 
12/07
NCT00034138: A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Terminated
1/2
24
US
oregovomab
Unither Pharmaceuticals
Ovarian Neoplasms
 
12/07

Download Options